Hinge Health, INC

Hinge Health announced record Q2 2026 results with 53% revenue growth to $213 million and tripling free cash flow, alongside a definitive agreement to acquire Cylinder Health for $105 million to expand into gastrointestinal care.

Hinge Health announced an increase in its revenue and operating margin guidance for Q2 and full year 2026, coinciding with its inaugural Investor Day event.

Hinge Health, Inc. successfully concluded its 2026 Annual Meeting, confirming the election of directors and the appointment of its independent auditor.

Hinge Health announced record first quarter 2026 financial results with 47% year-over-year revenue growth and raised its full-year revenue outlook.

Hinge Health, Inc. announced the immediate appointment of Tyler Sloat to its Board of Directors, where he will chair the Compensation Committee and serve on the Audit Committee.

Hinge Health announced record financial results for the fourth quarter and full year 2025, driven by strong commercial momentum and expanding margins.

Hinge Health, Inc. announced a 53% year-over-year revenue increase for the second quarter of 2026, alongside significant improvements in gross margin, driven by operational efficiencies and reduced stock-based compensation.

Hinge Health, Inc. announced a 47% year-over-year revenue increase for the first quarter of 2026, driven by strong client retention and member growth.

Hinge Health, Inc. reports a 53% revenue increase for Q3 2025, reaching $154.2 million, alongside a significant widening of net loss to $560.4 million for the nine months ended September 30, 2025, primarily due to IPO-related stock-based compensation.

Hinge Health, Inc. announced significant revenue growth and positive cash flow in its latest quarterly report, despite a substantial net loss driven by IPO-related stock-based compensation.

Hinge Health reports significant revenue growth and member expansion in 2025, alongside a substantial net loss driven by IPO-related stock compensation.

Teddie Benjamin Wardi, a Director of Hinge Health, Inc., reported a transaction in 4,637 shares of common stock on August 10, 2026.

Gabriel M.I. Mecklenburg, a Director of Hinge Health, Inc., reported multiple transactions in common stock on August 4, 2026.

James Pursley, President of Hinge Health, Inc., reported a transaction in 831 shares of common stock on August 1, 2026.

James Budge, Chief Financial Officer of Hinge Health, Inc., reported a transaction in 4,614 shares of common stock on August 1, 2026.

Gabriel M.I. Mecklenburg, a Director of Hinge Health, Inc., received 944,250 shares of common stock on July 27, 2026.

Daniel Antonio Perez, CEO & Co-Founder, a Director and 10% owner of Hinge Health, Inc., reported multiple transactions in common stock on July 27, 2026.

Hinge Health, Inc. has issued its definitive proxy statement for the 2026 Annual Meeting of Stockholders to be held virtually on June 3, 2026.

Hinge Health, a technology platform focused on transforming musculoskeletal care, has filed an S-1/A form for its initial public offering, planning to list on the NYSE under the symbol HNGE.

Hinge Health, a digital musculoskeletal (MSK) care company, has filed an S-1/A form with the SEC for its initial public offering (IPO), seeking to transform healthcare delivery through technology and AI.

Hinge Health, a technology-driven healthcare company focused on musculoskeletal (MSK) care, has filed an S-1/A form indicating its intent to go public, seeking to transform outcomes, experience, and costs in the healthcare system.

Hinge Health, a leading technology platform for musculoskeletal (MSK) care, has filed for an IPO to further its mission of transforming outcomes, experience, and costs through technology.

Hinge Health, a leading technology platform for musculoskeletal (MSK) care, has filed for an IPO, seeking to transform the industry with its AI-powered motion tracking and personalized care programs.

Insight Venture Partners entities have filed an amendment to their Schedule 13G, reporting changes in their beneficial ownership of Hinge Health, Inc. Class A Common Stock.

11.2 Capital entities and Qian Zhuang have collectively reported beneficial ownership of 2,464,657 shares of Hinge Health's Class A Common Stock, representing 4.0% of the outstanding shares.

Atomico Advisors IV, Ltd. and its affiliates have reported beneficial ownership of 2,300,000 shares of Hinge Health, Inc. Class A Common Stock, representing 2.88% of the class.

Hansa Invest, a German investment management company, has disclosed beneficial ownership of 1,476,600 ordinary shares in Hinge Health, Inc., representing 2.7% of the class.

The Vanguard Group filed an amended Schedule 13G, reporting 0% beneficial ownership in Hinge Health Inc. following an internal realignment.

Daniel Antonio Perez, a U.S. citizen, reported beneficial ownership of 15.7% of Hinge Health, Inc.'s Class A Common Stock as of December 31, 2025.